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Abstract
Background: Apurinic/apyrimidinic endonuclease 1 (APE1) has a central role in the repair of apurinic apyrimidic sites
through both its endonuclease and its phosphodiesterase activities. A common APE1 polymorphism, T1349G (rs3136820),
was previously shown to be associated with the risk of cancers.
Objective: We hypothesized that the APE1 T1349G polymorphism is also associated with risk of gastric cancer.
Methods: In a hospital-based case-control study of 338 case patients with newly diagnosed gastric cancer and 362 cancer-
free controls frequency-matched by age and sex, we genotyped the T1349G polymorphism and assessed its associations
with risk of gastric cancer.
Results: Compared with the APE1 TT genotype, individuals with the variant TG/GG genotypes had a significantly increased
risk of gastric cancer (odds ratio=1.69, 95% confidence interval=1.19–2.40), which was more pronounced among
subgroups of aged #60 years, male, ever smokers, and ever drinkers. Further analyses revealed that the variant genotypes
were associated with an increased risk for diffuse-type, low depth of tumor infiltration (T1 and T2), and lymph node
metastasis gastric cancer.
Conclusions: The APE1 T1349G polymorphism may be a marker for the development of gastric cancer in the Chinese
population. Larger studies are required to validate these findings in diverse populations.
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Introduction
Gastric cancer is the fourth most common cancer and the
second leading cause of cancer-related death worldwide, approx-
imately 700,000 people die of this malignancy each year, and
around 1.1 million new cases are expected in 2010 [1]. In China, it
was predicted to rank as the third most common cancer in 2005,
with 0.3 million deaths and 0.4 million new cases from gastric
cancer [2]. Although it is well known that environmental factors,
dietary habits, and Helicobacter pylori infection are associated with
the risk of gastric cancer, host genetic factors may be one of the
most critical agents in gastric carcinogenesis. Presentation of
gastric cancer in young patients is frequently associated with
familial clustering [3].
DNA damage induced by exogenous carcinogens or by
endogenous metabolic processes can be converted into gene
mutations leading to genomic instability and malignant transfor-
mation [4]. Genetic variations in DNA repair genes can modulate
DNA repair capacity and, consequently, alter cancer risk. About
150 human DNA repair genes have been identified to data [5].
They are cooperating in distinct pathways that are specialized in
the repair of the different types of DNA damage [6,7]. Among
these pathways, the base excision repair (BER) pathway, which
possibly handles the largest number of cytotoxic and mutagenic
base lesions, has been associated with risk of cancers [8].
The human apurinic/apyrimidinic endonuclease (APE), APE1
(also known as APE, APEX, and REF-1), is involved in the BER
pathway [9]. The APE1 gene is located on chromosome 14q11.2-
q12, and consists of five exons spanning 2.21 kb. By hydrolyzing
39-blocking fragments from oxidized DNA, APE1 produces normal
39-hydroxyl nucleotide termini that are necessary for DNA repair
synthesis and ligation at single- or double-strand breaks [10,11]. A
total of 18 polymorphisms in APE1 have been reported [12], but
the most extensively studied polymorphism is the T to G
transversion (T1349G, also known as Asp148Glu, rs3136820).
Recently, we have carried out a meta-analysis on all eligible
case-control studies to estimate the APE1 T1349G polymorphism
and risk of cancers, including lung cancer, bladder cancer,
colorectal cancer, breast cancer, pancreatic cancer, head and
neck cancer, leukaemia, esophageal cancer, biliary tract cancer,
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T1349G variant genotypes were associated with a moderately
increased risk of all cancer types (OR=1.08, 95%CI=1.00–1.18
in a dominant model), suggesting that this polymorphism is a low-
penetrance risk factor for cancer development [13]. More recently,
some studies reported the APE1 T1349G polymorphism was
associated with gastric cancer risk and prognosis [14,15,16,17].
However, these epidemiologic results remain conflicting rather
than conclusive.
In the present study, to investigate the effect of the APE1
T1349G polymorphism on the risk of gastric cancer, we
genotyped the polymorphism and evaluated the association
between the APE1 T1349G polymorphism and the risk of gastric
cancer in our ongoing, hospital-based, case-control study in a
Chinese population.
Materials and Methods
Ethics Statement
The ethics committee of Nanjing Medical University has
approved the research protocol. During epidemiological interviews,
written informed consent was given to all subjects. Furthermore,
trained research staff administered a standard questionnaire to
obtain information on demographic characteristics.
Study subjects
The detailed methods of recruiting study subjects for this study
have been described previously [18]. Briefly, 338 newly diagnosed,
histopathologically confirmed gastric cancer patients and 362
cancer-free control subjects were recruited from the cities of
Yangzhong and Yixin, two regions of high incidence and mortality
rate of gastric cancer in Jiangsu Province of China between March
2006 and July 2008. The exclusion criteria included previous
cancer, metastasized cancer from other or unknown origins, and
previous radiotherapy or chemotherapy. Controls were frequency-
matched to the cases by age (65 years) and sex. The cancer-free
control subjects were recruited from those who were seeking
health care, living in the same residential areas. Before
recruitment, informed consent was obtained from each of the
eligible subjects. For each individual, demographic information as
well as data on smoking status and alcohol use was obtained
through face-to-face interviews. Individuals who smoked once a
day for more than 1 year were defined as ever smokers. Ever
smokers who had quit smoking for more than 1 year were defined
as former smokers, and the other smokers as current smokers.
Individuals who consumed one or more alcoholic drinks per week
for at least 1 year were considered ever drinkers, and the rest were
defined as never drinkers. After interview, about 5 ml venous
blood sample was collected from each participant.
Genotyping
Genomic DNA was extracted from peripheral blood lympho-
cytes by proteinase K digestion, followed by phenol-chloroform
extraction and ethanol precipitation [19]. The APE1 T1349G
polymorphism was determined using the polymerase chain
reaction-restriction fragment length polymorphism (PCR-RFLP)
method, which has been described previously [20,21]. We
designed the primer of 59-TAATTCTGTTTCATTTCTATAG-
GCTA-39 (forward) and 59-TGCATTAGGTACATATGCTG-
TT-39 (reverse) to amplify the target fragment of APE1. Samples
were subjected to denaturation at 95uC for 5 min, followed by 30
cycles of heating at 95uC for 30 s, annealing at 55uC for 40 s, then
extension at 72uC for 45 s, and a final incubation at 72uC for
10 min. The PCR products of 108 bp were digested by the FspBI
restriction enzyme, to identify genotypes of the T1349G
polymorphism. After the enzyme digestion, the variant G allele
produced 2 fragments of 82-bp and 20-bp, and the wild-type T
allele resulted in a single 108-bp fragment.
The genotype analyses were performed by two persons
independently in a blind fashion. About 10% of the samples were
randomly selected for confirmation, and the results were fully
concordant.
Statistical analysis
Differences between cases and controls in selected demographic
variables, smoking status, alcohol use, and each allele and
genotype of the polymorphisms of APE1 gene were evaluated
using the Chi-square test. Chi-square test was also used to assess
the difference between the APE1 polymorphism and clinicopath-
ologic characteristics. The associations between APE1 genotypes
and the risk of gastric cancer were estimated by computing the
odds ratios (ORs) and their 95% confidence intervals (CIs) from
unconditional univariate and multivariate logistic regression
analyses. These analyses were repeated by stratifying for sex
(male, female), smoking status (never, ever) and drinking status (no,
yes). For stratification by age, the age cutoff at 60 years was used in
this study as it was the median age of the recruited patients and
controls. Furthermore, the genotypic-specific risks were also
estimated separately for cardia/noncardia tumor site, intestinal/
diffuse histotype, T1/T2/T3/T4 depth of tumor infiltration and
negative/positive lymph node metastasis. Hardy-Weinberg equi-
librium of the controls’ genotype distributions was tested by a
goodness-of-fit chi-square test. Two-sided tests of statistical
significance were conducted by using the SAS software (version
8.2; SAS Institute, Inc., Cary, NC).
Results
Distribution of selected characteristics between the gastric cancer
cases and control subjects are summarized in Table 1. According to
the genotyping results and questionnaire data, we included 338
gastric cancer cases and 362 cancer-free controls who had all these
data available in this analysis. The mean age at diagnosis for the
gastric cancer cases was 61.7 years (standard deviation (SD)612.3)
and mean age at ascertainment for the controls was 62.4 years
((SD)610.5). There were no statistically significant differences
between cases and controls in the distribution of age and sex.
However, higher incidences of smoking and drinking are associated
with gastric cancer (P,0.05). Furthermore, patients with cancer of
the gastric cardia and non-cardia were 143 (42.3%) and 195
(57.5%), respectively. The histological types were 192 (56.8%) for
intestinaland146(43.2%)fordiffusegastriccancer.Forthe depthof
tumor infiltration, T1, T2, T3, and T4 were 104 (30.8%), 64
(18.9%), 126 (37.3%), and 44 (13.0%), respectively. And positive
lymph nodes were identified in 174 (51.5%) cases.
The genotype and allele frequencies of the APE1 T1349G
polymorphism among the cases and controls and the associations
with risk of gastric cancer are shown in Table 2. The frequencies
of the TT, TG, and GG genotypes were 20.4%, 54.7%, and
24.9% in the cancer group, versus 30.4%, 50.5%, and 19.1% in
normal healthy individuals, respectively. The frequency of G allele
was 52.2% among cases, which was significantly greater than that
in controls 44.3% (P=0.003). A subsequent analysis revealed a
significant association of heterozygous (TG) and homozygous (GG)
variant genotype of APE1 T1349G with the risk of gastric cancer
(OR=1.61, 95% CI=1.12–2.32 for TG versus TT, and
OR=1.92, 95% CI=1.23–2.99 for GG versus TT, respectively).
In addition, we found that individuals with the variant TG/GG
APE1 T1349G Polymorphism and Gastric Cancer Risk
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those with the TT genotype (OR=1.69, 95% CI=1.19–2.40).
Further stratified analyses showed that the increased risk was more
evident in subgroups of aged#60 years (OR=2.00, 95%
CI=1.11–3.61), male (OR=1.65, 95% CI=1.07–2.55), ever
smokers (OR=2.00, 95% CI=1.14–3.05), and ever drinkers
(OR=2.18, 95% CI=1.18–4.03) (Table 3). However, because of
the limited study sample size, all the results from stratified analyses
were preliminary.
Association between the APE1 T1349G polymorphism and
clinicopathologic characteristics of gastric cancer risk stratified on
tumor site, histological type, depth of tumor infiltration and lymph
node metastasis are shown in Table 4. Statistical analysis revealed
a significant association of TG/GG genotypes with the risk of
cardia tumor and non-cardia tumor (OR=1.61, 95% CI=1.01–
2.56, and OR=1.79, 95% CI=1.17–2.73, respectively). Statisti-
cally, a trend toward a higher risk of diffuse-type gastric cancer
was detected for TG/GG genotypes (OR=2.09, 95% CI=1.29–
3.42), but there was no significant difference between intestinal-
type gastric cancers and normal controls (OR=1.46, 95%
CI=0.97–2.20). Further stratification analysis of depth of tumor
infiltration showed that the increased risk was more pronounced
between T1 (OR=2.73, 95% CI=1.50–4.99) and T2 (OR=2.17,
95% CI=1.08–4.33), but there were no significant differences
between distributions in subgroups of T3 and T4 (OR=1.28, 95%
CI=0.80–2.04, and OR=1.26, 95% CI=0.61–2.60, respective-
ly). In addition, there were a significant increased risk in node-
positive gastric cancer (OR=1.80, 95% CI=1.16–2.80), while not
in node-negative gastric cancer (OR=1.62, 95% CI=0.99–2.51)
with the TG/GG genotypes compared with the TT genotype.
Discussion
In this hospital-based case-control study, we investigated the
association of APE1 T1349G polymorphism and risk of gastric
cancer in Chinese populations. We found that the T1349G
polymorphism contributed to the risk of gastric cancer, which was
more pronounced among subgroups of aged#60 years, male, ever
smokers, and ever drinkers. Furthermore, the T1349G polymor-
phism was associated with an increased risk for diffuse-type, low
depth of tumor infiltration (T1 and T2), and lymph node
metastasis gastric cancer.
APE1 is an essential enzyme in the BER pathway, which is the
primary mechanism for the repair of DNA damage caused by
oxidation and alkylation [7]. The T1349G polymorphism is the
most common polymorphism that result in single amino acid
substitution has been identified in the general population [12]. It
has not been determined if the G variant allele has an impact on
endonuclease and DNA binding activities [22]. However, the GG
genotype has been associated with significantly prolonged cell
cycle G2 delays compared with the TT and TG genotypes, which
suggests that this amino acid substitution may contribute to
hypersensitivity to ionizing radiation [23]. Our study found that
the G variant allele was associated with a significantly increased
risk of gastric cancer, which is consistent with our previously
published meta-analysis results [13]. In previous studies, Canbay
et al. [15] found significant differences in the frequencies of G
allele of APE1 T1349G polymorphism between gastric cancer
patients and control subjects in a Turkish population. Neverthe-
less, Palli et al. [16] did not observe significant association of this
polymorphism with gastric cancer in their study. The reason for
these different findings remains unclear, which might due to small
sample sizes or ethnically diverse.
In the addition, we found that the T1349G polymorphism was
associated with increased risk of gastric cancer among subgroups
of younger subjects (age#60 years) but not older subjects. Weak
immune system and overwhelming accumulated exposure to
environmental carcinogens in older individuals may account for
the age difference we observed [24]. The older individuals are at a
higher risk of gastric cancer, which is more likely due to the aging
Table 1. Distribution of selected variables between the
gastric cancer cases and control subjects.
Variables
Cases
(n=338)
Controls
(n=362) P
n % n %
Age (years) (mean 6 SD) 61.7612.3 62.4610.5 0.469
a
Sex
Male 222 65.7 239 66.0 0.924
b
Female 116 34.3 123 34.0
Smoking status
Never 182 53.9 231 63.8 0.007
b
Ever 156 46.1 131 36.2
Drinking status
No 212 62.7 258 71.3 0.016
b
Yes 126 37.3 104 28.7
Tumor site
Cardia 143 42.3
Non-cardia 195 57.5
Histological type
Intestinal 192 56.8
Diffuse 146 43.2
Depth of tumor infiltration
T1 104 30.8
T2 64 18.9
T3 126 37.3
T4 44 13.0
Lymph node metastasis
Negative 164 48.5
Positive 174 51.5
aTwo-sided t-test for difference between the cases and controls.
bTwo-sided x
2 test for distribution between the cases and controls.
doi:10.1371/journal.pone.0028971.t001
Table 2. Genotype and allele frequencies of the APE1 T1349G
polymorphism among the cases and controls and the
associations with risk of gastric cancer.
APE1
T1349G
Cases
(n=338)
Controls
(n=362) OR (95% CI)
a P
n % n %
TT 69 20.4 110 30.4 1.00 (ref.)
TG 185 54.7 183 50.5 1.61 (1.12–2.32) 0.011
GG 84 24.9 69 19.1 1.92 (1.23–2.99) 0.004
TG/GG 269 75.6 252 69.6 1.69 (1.19–2.40) 0.003
aAdjusted for age, sex, smoking, and alcohol status in logistic regression model.
doi:10.1371/journal.pone.0028971.t002
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the APE1 gene may be more influential in early-onset gastric
cancer, although this result needs more confirmations. Tobacco
smoke contains hundreds of chemicals, which was unequivocally
established as the main causative factor for gastric cancer [25].
Our results indicated that the risk associated with the T1349G
polymorphism was more evident in smokers. This may be because
cigarette smoke generates reactive oxygen species production and
induces DNA adducts [26]. Studies have reported that increase
alcohol intake may increase risk of cancer, including gastric cancer
[27]. Consistently, our results also revealed that subjects who have
ever consumed alcohol with the T1349G polymorphism have an
increased risk of gastric cancer. However, our small sample size
might not have a sufficient power to detect the significant gene-
environment interaction; thus, larger studies with more detailed
environmental exposure data are needed to verify these findings.
Intestinal and diffuse types have different epidemiology and
pathogenesis. The intestinal-type gastric cancer is international
variation and predominates in high-risk geographic areas,
especially in Japan, Korea and China, whereas the diffuse-type
gastric cancer has uniform geographic distributions [28,29].
Environmental factors have been proposed to play an important
role in the etiology of intestinal-type gastric cancer, and the genetic
susceptibility factors may contributed more to diffused-type gastric
cancer development. Interestingly, we found that the effect of the
T1349G polymorphism was associated with diffused-type gastric
cancer but not intestinal-type gastric cancer. Furthermore, we
found that the T1349G polymorphism was associated with an
increased risk for low depth of tumor infiltration (T1 and T2), and
lymph node metastasis gastric cancer, which may serve as a
biomarker of gastric cancer metastasis. However, because the
detectable effect size in our study was relatively small (n=11 for
TT genotype in the T1 and T2 subgroups), the clinical utility of
our findings should be interpreted with precaution. Furthermore,
the biological mechanism in relation to APE1 variant, the APE1
gene expression, and gastric cancer development and metastasis
remain to be explored.
In conclusion, our study suggests that the APE1 T1349G
polymorphism may be associated with risk of gastric cancer
development in Chinese populations. Large population-based
prospective studies with ethnically diverse populations are
warranted to verify these findings.
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Table 4. Association between the APE1 T1349G
polymorphism and clinicopathologic characteristics of gastric
cancer risk.
APE1 T1349G Genotype TG/GG vs. TT
TT TG/GG P OR (95% CI)
a
Controls (n=362) 110 252 1.00 (ref.)
Cases (n=338) 69 269
Tumor site
Cardia 43 151 0.046 1.61 (1.01–2.56)
Non-cardia 26 118 0.007 1.79 (1.17–2.73)
Histological type
Intestinal 44 148 0.072 1.46 (0.97–2.20)
Diffuse 25 121 0.003 2.09 (1.29–3.42)
Depth of tumor infiltration
T1 15 89 0.001 2.73 (1.50–4.99)
T2 11 53 0.029 2.17 (1.08–4.33)
T3 32 94 0.303 1.28 (0.80–2.04)
T4 11 33 0.537 1.26 (0.61–2.60)
Lymph node metastasis
Negative 35 129 0.051 1.62 (0.99–2.51)
Positive 34 140 0.009 1.80 (1.16–2.80)
aAdjusted for age, sex, smoking, and alcohol status in logistic regression model.
doi:10.1371/journal.pone.0028971.t004
Table 3. Stratified analyses for the APE1 T1349G polymorphism in gastric cancer cases and control subjects.
Variables TT genotype TG/GG genotypes TG/GG vs. TT
Cases Controls Cases Controls OR (95% CI)
a
N( % ) N( % ) N( % ) N( % )
Age (years)
#60 26 (18.3) 35 (31.5) 116 (81.7) 76 (68.5) 2.00 (1.11–3.61)
.60 43 (21.9) 75 (29.9) 153 (78.1) 176 (70.1) 1.49 (0.96–2.31)
Sex
Male 45 (20.3) 71 (29.7) 177 (79.7) 168 (70.3) 1.65 (1.07–2.55)
Female 24 (20.7) 39 (31.7) 92 (79.3) 84 (68.3) 1.72 (0.95–3.12)
Smoking status
Never 41 (22.5) 71 (30.7) 141 (77.5) 160 (69.3) 1.50 (0.96–2.36)
Ever 28 (18.0) 39 (29.8) 128 (82.0) 92 (70.2) 2.00 (1.14–3.05)
Drinking status
No 45 (21.2) 73 (28.3) 167 (78.8) 185 (71.7) 1.47 (0.96–2.25)
Yes 24 (19.1) 37 (35.6) 102 (80.9) 67 (64.4) 2.18 (1.18–4.03)
aAdjusted for age, sex, smoking, and alcohol status in logistic regression model.
doi:10.1371/journal.pone.0028971.t003
APE1 T1349G Polymorphism and Gastric Cancer Risk
PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e28971References
1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA
Cancer J Clin 55: 74–108.
2. Yang L (2006) Incidence and mortality of gastric cancer in China. World
J Gastroenterol 12: 17–20.
3. Ramos-De la Medina A, Salgado-Nesme N, Torres-Villalobos G, Medina-
Franco H (2004) Clinicopathologic characteristics of gastric cancer in a young
patient population. J Gastrointest Surg 8: 240–244.
4. Friedberg EC (2001) How nucleotide excision repair protects against cancer. Nat
Rev Cancer 1: 22–33.
5. Wood RD, Mitchell M, Lindahl T (2005) Human DNA repair genes, 2005.
Mutat Res 577: 275–283.
6. Christmann M, Tomicic MT, Roos WP, Kaina B (2003) Mechanisms of human
DNA repair: an update. Toxicology 193: 3–34.
7. Hoeijmakers JH (2001) Genome maintenance mechanisms for preventing
cancer. Nature 411: 366–374.
8. Wilson DM, 3rd, Bohr VA (2007) The mechanics of base excision repair, and its
relationship to aging and disease. DNA Repair (Amst) 6: 544–559.
9. Wood RD, Mitchell M, Sgouros J, Lindahl T (2001) Human DNA repair genes.
Science 291: 1284–1289.
10. Izumi T, Hazra TK, Boldogh I, Tomkinson AE, Park MS, et al. (2000)
Requirement for human AP endonuclease 1 for repair of 39-blocking damage at
DNA single-strand breaks induced by reactive oxygen species. Carcinogenesis
21: 1329–1334.
11. Kelley MR, Cheng L, Foster R, Tritt R, Jiang J, et al. (2001) Elevated and
altered expression of the multifunctional DNA base excision repair and redox
enzyme Ape1/ref-1 in prostate cancer. Clin Cancer Res 7: 824–830.
12. Xi T, Jones IM, Mohrenweiser HW (2004) Many amino acid substitution
variants identified in DNA repair genes during human population screenings are
predicted to impact protein function. Genomics 83: 970–979.
13. Gu D, Wang M, Wang M, Zhang Z, Chen J (2009) The DNA repair gene APE1
T1349G polymorphism and cancer risk: a meta-analysis of 27 case-control
studies. Mutagenesis 24: 507–512.
14. Li WQ, Zhang L, Ma JL, Zhang Y, Li JY, et al. (2009) Association between
genetic polymorphisms of DNA base excision repair genes and evolution of
precancerous gastric lesions in a Chinese population. Carcinogenesis 30:
500–505.
15. Canbay E, Agachan B, Gulluoglu M, Isbir T, Balik E, et al. (2010) Possible
associations of APE1 polymorphism with susceptibility and HOGG1 polymor-
phism with prognosis in gastric cancer. Anticancer Res 30: 1359–1364.
16. Palli D, Polidoro S, D’Errico M, Saieva C, Guarrera S, et al. (2010) Polymorphic
DNA repair and metabolic genes: a multigenic study on gastric cancer.
Mutagenesis 25: 569–575.
17. Zhao Q, Wang W, Zhang Z, Wang S, Wang M, et al. (2011) A genetic variation
in APE1 is associated with gastric cancer survival in a Chinese population.
Cancer Sci 102: 1293–1297.
18. Wu D, Tian Y, Gong W, Zhu H, Zhang Z, et al. (2009) Genetic variants in the
Runt-related transcription factor 3 gene contribute to gastric cancer risk in a
Chinese population. Cancer Sci 100: 1688–1694.
19. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for
extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215.
20. Misra RR, Ratnasinghe D, Tangrea JA, Virtamo J, Andersen MR, et al. (2003)
Polymorphisms in the DNA repair genes XPD, XRCC1, XRCC3, and APE/
ref-1, and the risk of lung cancer among male smokers in Finland. Cancer Lett
191: 171–178.
21. Popanda O, Schattenberg T, Phong CT, Butkiewicz D, Risch A, et al. (2004)
Specific combinations of DNA repair gene variants and increased risk for non-
small cell lung cancer. Carcinogenesis 25: 2433–2441.
22. Hadi MZ, Coleman MA, Fidelis K, Mohrenweiser HW, Wilson DM, 3rd (2000)
Functional characterization of Ape1 variants identified in the human population.
Nucleic Acids Res 28: 3871–3879.
23. Hu JJ, Smith TR, Miller MS, Mohrenweiser HW, Golden A, et al. (2001) Amino
acid substitution variants of APE1 and XRCC1 genes associated with ionizing
radiation sensitivity. Carcinogenesis 22: 917–922.
24. Zhu H, Yang L, Zhou B, Yu R, Tang N, et al. (2006) Myeloperoxidase G-463A
polymorphism and the risk of gastric cancer: a case-control study. Carcinogen-
esis 27: 2491–2496.
25. Parkin DM (2004) International variation. Oncogene 23: 6329–6340.
26. Hecht SS (2002) Tobacco smoke carcinogens and breast cancer. Environ Mol
Mutagen 39: 119–126.
27. Crew KD, Neugut AI (2004) Epidemiology of upper gastrointestinal malignan-
cies. Semin Oncol 31: 450–464.
28. CrewKD,NeugutAI(2006)Epidemiologyofgastriccancer.WorldJGastroenterol
12: 354–362.
29. Li ZX, Kaminishi M (2009) A comparison of gastric cancer between Japan and
China. Gastric Cancer 12: 52–53.
APE1 T1349G Polymorphism and Gastric Cancer Risk
PLoS ONE | www.plosone.org 5 December 2011 | Volume 6 | Issue 12 | e28971